Author

Patricia Iranzo

h-index 5 View on Semantic Scholar

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial.

BACKGROUND MET and angiogenic pathways are activated in EGFR-mutant non-small-cell lung cancer (NSCLC) upon resistance to tyrosine-kinase inhibitors (TKIs). Amivantamab, an EGFR and MET bispecific antibody, is approved in combination with chemotherapy for EGFR-mutant NSCLC post-osimertinib progression based on results...

R. Soo, Sanjay Popat, U. Dafni et al. · The Lancet Respiratory Medic... · 0 citations

#artificial intelligence Open access Sep 2026

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.

A. Prelaj, V. Mišković, Matteo Sacco et al. · Nature Medicine · 1 citation